Linaglu 5 Tablet contains Linagliptin 5 mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Linagliptin enhances the incretin system by inhibiting the DPP-4 enzyme, thereby increasing the levels of active incretin hormones such as GLP-1 and GIP. This mechanism results in glucose-dependent stimulation of insulin secretion and suppression of glucagon release, leading to improved glycemic control without causing significant hypoglycemia. Linaglu 5 is prescribed as monotherapy or in combination with other antidiabetic agents, including metformin, sulfonylureas, or insulin, to achieve optimal blood glucose regulation. The drug is characterized by its once-daily oral dosing and favorable pharmacokinetic profile, including minimal renal excretion, making it suitable for patients with varying degrees of renal impairment without dose adjustment. Common adverse effects are generally mild and may include nasopharyngitis, headache, and upper respiratory tract infections. Linaglu 5 should be used with caution in patients with a history of pancreatitis. Regular monitoring of glycemic parameters and renal function is recommended during therapy. This medication should be prescribed and used under medical supervision as part of a comprehensive diabetes management plan incorporating diet and exercise.